CSTL vs. FCX

Last updated Apr 1, 2026

Compare and contrast key facts about Castle Biosciences, Inc. (CSTL) and Freeport-McMoRan Inc. (FCX).

Performance

CSTL vs. FCX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Castle Biosciences, Inc. (CSTL) and Freeport-McMoRan Inc. (FCX). The values are adjusted to include any dividend payments, if applicable.

CSTL vs. FCX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
CSTL Castle Biosciences, Inc.	-36.89%	45.97%	23.49%	-8.33%	-45.09%	-36.16%	95.37%	60.61%
FCX Freeport-McMoRan Inc.	16.02%	35.41%	-9.41%	13.69%	-7.91%	61.41%	99.06%	15.53%

Fundamentals

Market Cap CSTL : $720.13M FCX : $84.82B
EPS CSTL : -$0.82 FCX : $1.91
PS Ratio CSTL : 2.09 FCX : 3.30
PB Ratio CSTL : 1.53 FCX : 4.49
Total Revenue (TTM) CSTL : $344.23M FCX : $25.74B
Gross Profit (TTM) CSTL : $204.51M FCX : $6.95B
EBITDA (TTM) CSTL : $8.22M FCX : $8.76B

Returns By Period

In the year-to-date period, CSTL achieves a -36.89% return, which is significantly lower than FCX's 16.02% return.

CSTL

• 1D: 4.25%
• 1M: -16.98%
• YTD: -36.89%
• 6M: 7.82%
• 1Y: 22.63%
• 3Y*: 2.62%
• 5Y*: -19.15%
• 10Y*: —

FCX

• 1D: 7.56%
• 1M: -13.66%
• YTD: 16.02%
• 6M: 50.78%
• 1Y: 57.42%
• 3Y*: 14.42%
• 5Y*: 13.14%
• 10Y*: 20.64%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

CSTL vs. FCX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CSTL

CSTL Risk / Return Rank: 56
CSTL Sharpe Ratio Rank: 55
CSTL Sortino Ratio Rank: 58
CSTL Omega Ratio Rank: 55
CSTL Calmar Ratio Rank: 54
CSTL Martin Ratio Rank: 55

FCX

FCX Risk / Return Rank: 77
FCX Sharpe Ratio Rank: 78
FCX Sortino Ratio Rank: 71
FCX Omega Ratio Rank: 74
FCX Calmar Ratio Rank: 80
FCX Martin Ratio Rank: 80

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CSTL vs. FCX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Castle Biosciences, Inc. (CSTL) and Freeport-McMoRan Inc. (FCX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CSTL	FCX	Difference
Sharpe ratio Return per unit of total volatility	0.38	1.14	-0.76
Sortino ratio Return per unit of downside risk	1.09	1.58	-0.50
Omega ratio Gain probability vs. loss probability	1.13	1.23	-0.10
Calmar ratio Return relative to maximum drawdown	0.51	2.21	-1.70
Martin ratio Return relative to average drawdown	1.30	5.81	-4.51
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CSTL vs. FCX - Sharpe Ratio Comparison

The current CSTL Sharpe Ratio is 0.38, which is lower than the FCX Sharpe Ratio of 1.14. The chart below compares the historical Sharpe Ratios of CSTL and FCX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	CSTL	FCX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.38	1.14	-0.76
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.26	0.30	-0.56
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.42	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.03	0.15	-0.12

Correlation

The correlation between CSTL and FCX is 0.19, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

CSTL vs. FCX - Dividend Comparison

CSTL has not paid dividends to shareholders, while FCX's dividend yield for the trailing twelve months is around 1.02%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
CSTL Castle Biosciences, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
FCX Freeport-McMoRan Inc.	1.02%	1.18%	1.58%	1.41%	0.99%	0.54%	0.19%	1.52%	1.45%	0.00%	0.00%	8.46%

Drawdowns

CSTL vs. FCX - Drawdown Comparison

The maximum CSTL drawdown since its inception was -88.02%, roughly equal to the maximum FCX drawdown of -92.52%. Use the drawdown chart below to compare losses from any high point for CSTL and FCX.

Drawdown Indicators

	CSTL	FCX	Difference
Max Drawdown Largest peak-to-trough decline	-88.02%	-92.52%	+4.50%
Max Drawdown (1Y) Largest decline over 1 year	-45.33%	-24.90%	-20.43%
Max Drawdown (5Y) Largest decline over 5 years	-84.97%	-51.47%	-33.50%
Max Drawdown (10Y) Largest decline over 10 years	—	-72.59%	—
Current Drawdown Current decline from peak	-74.78%	-14.59%	-60.19%
Average Drawdown Average peak-to-trough decline	-54.08%	-39.82%	-14.26%
Ulcer Index Depth and duration of drawdowns from previous peaks	17.78%	9.48%	+8.30%

Volatility

CSTL vs. FCX - Volatility Comparison

The current volatility for Castle Biosciences, Inc. (CSTL) is 9.82%, while Freeport-McMoRan Inc. (FCX) has a volatility of 16.77%. This indicates that CSTL experiences smaller price fluctuations and is considered to be less risky than FCX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CSTL	FCX	Difference
Volatility (1M) Calculated over the trailing 1-month period	9.82%	16.77%	-6.95%
Volatility (6M) Calculated over the trailing 6-month period	36.73%	31.53%	+5.20%
Volatility (1Y) Calculated over the trailing 1-year period	59.76%	50.77%	+8.99%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	73.92%	44.70%	+29.22%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	74.42%	49.31%	+25.11%

Financials

CSTL vs. FCX - Profitability Comparison

The chart below illustrates the profitability comparison between Castle Biosciences, Inc. and Freeport-McMoRan Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

CSTL - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Castle Biosciences, Inc. reported a gross profit of 0.00 and revenue of 87.01M. Therefore, the gross margin over that period was 0.0%.

FCX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Freeport-McMoRan Inc. reported a gross profit of 1.02B and revenue of 5.63B. Therefore, the gross margin over that period was 18.1%.

CSTL - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Castle Biosciences, Inc. reported an operating income of -3.83M and revenue of 87.01M, resulting in an operating margin of -4.4%.

FCX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Freeport-McMoRan Inc. reported an operating income of 811.00M and revenue of 5.63B, resulting in an operating margin of 14.4%.

CSTL - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Castle Biosciences, Inc. reported a net income of -2.33M and revenue of 87.01M, resulting in a net margin of -2.7%.

FCX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Freeport-McMoRan Inc. reported a net income of 968.00M and revenue of 5.63B, resulting in a net margin of 17.2%.